Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936538 | PMC |
| http://dx.doi.org/10.1016/j.remnie.2021.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the correlation between pretreatment F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival.
Pathol Oncol Res
January 2025
Department of Nuclear Medicine, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, Istanbul, Türkiye.
Background And Objectives: This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.
Methods: We retrospectively analyzed data from 100 females with stage 2-4 NLBC who underwent pretreatment F-FDG Positron emission tomography-computed tomography (PET/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated.
Application of low-dose FDG-PET/MRI for quantification of lung changes in pediatric patients with cystic fibrosis: a new inflammatory index.
Quant Imaging Med Surg
January 2025
Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany.
Background: Clinical severity and progression of lung disease in cystic fibrosis (CF) are significantly influenced by the degree of lung inflammation. Non-invasive quantitative diagnostic tools are desirable to differentiate structural and inflammatory lung changes in order to help prevent chronic airway disease. This might also be helpful for the evaluation of longitudinal effects of novel therapeutics.
View Article and Find Full Text PDFAssessment of viable tumours by [Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Purpose: To investigate the efficacy of [Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed.
Methods: A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [F]FDG and [Ga]Ga-FAPI-04 was performed.
Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, F-FDG PET/CT, DNA mutation, and CA199.
Cancer Cell Int
January 2025
The Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, 321 Zhongshan Road, Nanjing, 210008, China.
Background: Immunotherapy and radiotherapy play crucial roles in the transformation therapy of locally advanced pancreatic cancer; however, the exploration of effective predictive biomarkers has been unsatisfactory. With the rapid development of radiomics, next-generation sequencing, and machine learning, there is hope to identify biomarkers that can predict the efficacy of transformative treatment for locally advanced pancreatic cancer through simple and non-invasive clinical methods. Our study focuses on using computed tomography (CT), positron emission tomography/computed tomography (PET/CT), gene mutations, and baseline carbohydrate antigen 199 (CA199) to identify biomarkers for predicting the efficacy of transformative treatment.
View Article and Find Full Text PDFA case of F-FDG PET/MR facilitates early diagnosis of anti-GFAP encephalitis disease.
Neurol Sci
January 2025
Department of Infectious Diseases, Shenzhen Nanshan People's Hospital, Shenzhen University Medical School, Shenzhen, 518052, China.
Background: Glial fibrillary acidic protein (GFAP) astrocytosis is a rare autoimmune encephalitis discovered in the last decade. The diagnosis depends on clinical symptoms, imaging, and antibody testing. However, most cases require several months or even longer to make a definite diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!